Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PHIRST-1: Tadalafil for Pulmonary Arterial Hypertension
NCT00125918Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Aug 2005
- Primary completion
- Aug 2007
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 3, randomised, double-blind trial of tadalafil in pulmonary arterial hypertension (PAH) (5 arms), sponsored by Eli Lilly and Company. Primary endpoint: 6-Minute Walk Distance at 16 weeks. Started Aug 2005; status: completed.
02
Drugs
tadalafil
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT00125918.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00125918.